Both stocks have huge opportunities still in front of them. When it comes to investing, sometimes you want to take a big swing. After all, it's not always the number of winners in your portfolio that ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

Hims and Hers stock rally looms with bullish EMAs, Novo Nordisk partnership, ZAVA acquisition, and new product launches ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

The reason Novo Nordisk is losing patent protection is because it wouldn't pay a couple hundred bucks. In 2019, the Canadian patent office sent a letter saying it hadn't received Novo Nordisk's annual ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...

Officials at the FDA say they want to speed up approvals for new drugs and devices using tech like the new "Elsa" AI system. More news is on other uses of AI in health care, Eli Lilly refusing to work ...

Hims & Hers (NYSE: HIMS) stock, a prominent player in the booming telehealth sector, has undeniably captured significant investor attention recently. Perhaps you, like many others, have been caught up ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...